Summary
Boston Scientific Corporation's (BSX) third quarter 2009 results, as reported in their 10-Q filing on November 5, 2009, indicate a challenging period marked by revenue declines and strategic repositioning. The company is actively managing its product portfolio and operational structure to navigate the economic downturn and improve its financial standing. Investors should pay close attention to the ongoing impact of divestitures and the company's efforts to drive growth in key strategic areas.
Financial Highlights
47 data pointsBeta
Financial Statements
Beta
| Revenue | $2.02B |
| Cost of Revenue | $629.00M |
| Gross Profit | $1.40B |
| SG&A Expenses | $665.00M |
| Operating Expenses | $1.34B |
| Operating Income | $51.00M |
| Interest Expense | $91.00M |
| Net Income | -$94.00M |
| EPS (Basic) | $-0.06 |
| EPS (Diluted) | $-0.06 |
| Shares Outstanding (Basic) | 1.51B |
| Shares Outstanding (Diluted) | 1.51B |
Key Highlights
- 1Revenue for the nine months ended September 29, 2009, decreased compared to the same period in 2008, reflecting both divestitures and underlying market conditions.
- 2The company reported a net loss for the nine months ended September 29, 2009, although this may include significant non-recurring charges or restructuring costs.
- 3Operating expenses were managed, but the company continued to invest in research and development to support future product pipelines.
- 4Cash flow from operations remained a key focus, with efforts to preserve liquidity amidst economic uncertainties.
- 5The company is actively engaged in divesting non-core assets and streamlining operations, impacting reported revenues and profitability.
- 6Management commentary highlights efforts to improve operational efficiency and financial flexibility.